SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Arcolab’s arm gets US FDA nod for Paclitaxle injection

30 Sep 2011 Evaluate

Onco Therapies, a division of Agila, which is a wholly owned subsidiary of Strides Arcolab, has received US Food and Drug Administration (FDA) approval for Paclitaxle injection USP, 6mg/ml packaged in 30mg/ml, 100mg/ml and 300mg/ml multiple dose vials.

Paclitaxle injection is among the products in the drug shortage list of the America Society of Health-System Pharmacists and the USFDA. The US market of Paclitaxle is about $46 million. The company will launch the product immediately.

The company has also got tentative approval for Oxaliplatin injection which has a US market of about $1.4 billion.

Recently, Onco Therapies received European Union (EU) approval for Oxaliplantin Injection 5mg/ml (10ml, 20ml and 40ml). This is the second European approval out of the 22 filings made by OTL in the year 2010 for products which have a combined market value of over $5 billion.

Strides Arcolab is global pharmaceuticals company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with emphasis on sterlite injectables.

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×